The NCCN ORP fosters innovation and knowledge discovery that improve the lives of patients with cancer.
Guiding Principles:
Now Accepting Abstracts for the 2025 NCCN Annual Conference General Poster Session - Submit an abstract by Wednesday, October 30, 2024.
NCCN and Taiho Request for Proposals (RFP) Opportunity: Phase I/II Clinical Trials of Tipiracil/Trifluridine (TAS-102) and/or Futibatinib (TAS-120) for Gastrointestinal Cancers – Submit proposals by Tuesday, November 12, 2024. Open to NCCN Member Institutions only.
View the NCCN ORP Press Releases
View the NCCN ORP Scientific Publications
View the NCCN ORP Disclosure Policy